Eculizumab was safe and effective in the management of transplant-associated thrombotic microangiopathy in a heart transplant recipient with concurrent COVID-19 infection

Internal Medicine JournalVolume 53, Issue 8 p. 1506-1508 Letter to the Editor Eculizumab was safe and effective in the management of transplant-associated thrombotic microangiopathy in a heart transplant recipient with concurrent COVID-19 infection Chi Xu, Chi Xu [email protected] orcid.org/0000-0003-3829-2187 Department of Renal Medicine, Alfred Health, Melbourne, Victoria, Australia Department of Renal Services, Western Health, Melbourne, Victoria, AustraliaSearch for more papers by this authorVincent Wong, Vincent Wong Department of Renal Medicine, Alfred Health, Melbourne, Victoria, Australia Department of Renal Services, Western Health, Melbourne, Victoria, AustraliaSearch for more papers by this authorAriefandi Kurniawan, Ariefandi Kurniawan Department of Renal Medicine, Alfred Health, Melbourne, Victoria, AustraliaSearch for more papers by this authorScott Wilson, Scott Wilson Department of Renal Medicine, Alfred Health, Melbourne, Victoria, Australia Central Clinical School, Faculty of Medicine, Nursing and Health Science, Monash University, Melbourne, Victoria, AustraliaSearch for more papers by this authorBasu Gopal, Basu Gopal orcid.org/0000-0002-8586-8743 Department of Renal Medicine, Alfred Health, Melbourne, Victoria, Australia Central Clinical School, Faculty of Medicine, Nursing and Health Science, Monash University, Melbourne, Victoria, AustraliaSearch for more papers by this authorPaul D. Lawton, Paul D. Lawton Department of Renal Medicine, Alfred Health, Melbourne, Victoria, Australia Central Clinical School, Faculty of Medicine, Nursing and Health Science, Monash University, Melbourne, Victoria, Australia Menzies School of Health Research, Darwin, Northwest Territories, AustraliaSearch for more papers by this author Chi Xu, Chi Xu [email protected] orcid.org/0000-0003-3829-2187 Department of Renal Medicine, Alfred Health, Melbourne, Victoria, Australia Department of Renal Services, Western Health, Melbourne, Victoria, AustraliaSearch for more papers by this authorVincent Wong, Vincent Wong Department of Renal Medicine, Alfred Health, Melbourne, Victoria, Australia Department of Renal Services, Western Health, Melbourne, Victoria, AustraliaSearch for more papers by this authorAriefandi Kurniawan, Ariefandi Kurniawan Department of Renal Medicine, Alfred Health, Melbourne, Victoria, AustraliaSearch for more papers by this authorScott Wilson, Scott Wilson Department of Renal Medicine, Alfred Health, Melbourne, Victoria, Australia Central Clinical School, Faculty of Medicine, Nursing and Health Science, Monash University, Melbourne, Victoria, AustraliaSearch for more papers by this authorBasu Gopal, Basu Gopal orcid.org/0000-0002-8586-8743 Department of Renal Medicine, Alfred Health, Melbourne, Victoria, Australia Central Clinical School, Faculty of Medicine, Nursing and Health Science, Monash University, Melbourne, Victoria, AustraliaSearch for more papers by this authorPaul D. Lawton, Paul D. Lawton Department of Renal Medicine, Alfred Health, Melbourne, Victoria, Australia Central Clinical School, Faculty of Medicine, Nursing and Health Science, Monash University, Melbourne, Victoria, Australia Menzies School of Health Research, Darwin, Northwest Territories, AustraliaSearch for more papers by this author First published: 20 August 2023 https://doi.org/10.1111/imj.16178Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol 2018; 13: 300–317. 2Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 2015; 125: 616–618. 3Tiwari NR, Phatak S, Sharma VR, Agarwal SK. COVID-19 and thrombotic microangiopathies. Thromb Res 2021; 202: 191–198. 4Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol 2013; 33: 508–530. 5Dhakal P, Giri S, Pathak R, Bhatt VR. Eculizumab in transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost 2017; 23: 175–180. Volume53, Issue8August 2023Pages 1506-1508 ReferencesRelatedInformation